A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Avitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 31 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Jun 2018 Planned number of patients changed from 366 to 354.
- 28 Jun 2018 Planned initiation date changed from 1 Dec 2017 to 1 Dec 2018.